Previous close | 9.27 |
Open | 9.28 |
Bid | 9.60 x 400 |
Ask | 9.66 x 100 |
Day's range | 9.20 - 9.71 |
52-week range | 3.81 - 17.70 |
Volume | |
Avg. volume | 294,831 |
Market cap | 567.291M |
Beta (5Y monthly) | 0.28 |
PE ratio (TTM) | N/A |
EPS (TTM) | -4.71 |
Earnings date | 10 May 2024 - 14 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 21.60 |
IGM Biosciences ( NASDAQ:IGMS ) Full Year 2023 Results Key Financial Results Net loss: US$246.4m (loss widened by 11...
IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 4.72% and 31.47%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
MOUNTAIN VIEW, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on recent developments. “We made significant progress during 2023 in the clinical development of our two lead product candidates in therapeutic areas that we believe have the greatest potentia